<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04100330</url>
  </required_header>
  <id_info>
    <org_study_id>AV-299-19-207</org_study_id>
    <nct_id>NCT04100330</nct_id>
  </id_info>
  <brief_title>A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <acronym>CyFi2</acronym>
  <official_title>A Phase 2, Randomized, Open-Label, Multicenter Study of Ficlatuzumab in Combination With High-Dose Cytarabine (HiDAC) and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biodesix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AVEO Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, open-label, multicenter study to evaluate the safety and&#xD;
      efficacy of ficlatuzumab in combination with high-dose cytarabine (HiDAC) and HiDAC alone in&#xD;
      subjects with relapsed or refractory acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Urgent shift among clinical sites toward efforts to combat COVID-19 pandemic;impacted&#xD;
    feasibility of completing study within shelf-life of current IP supply&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 31, 2020</start_date>
  <completion_date type="Actual">March 27, 2020</completion_date>
  <primary_completion_date type="Actual">March 27, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Approximately 13 months (through study treatment completion)</time_frame>
    <description>To estimate the overall response rate (ORR) (complete remission [CR] + CR with incomplete hematologic recovery [CRi]) of ficlatuzumab in combination with high-dose cytarabine (HiDAC) and HiDAC alone in adults with relapsed or refractory acute myeloid leukemia (AML)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>Approximately 14 months (through 30 days after the last subject completes treatment)</time_frame>
    <description>To evaluate the safety and tolerability of ficlatuzumab when administered with HiDAC and HiDAC alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>For up to one year after the end of study treatment</time_frame>
    <description>To estimate the overall survival (OS) rate of ficlatuzumab in combination with HiDAC and HiDAC alone in adults with relapsed or refractory AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS)</measure>
    <time_frame>For up to one year after the end of study treatment</time_frame>
    <description>To estimate the disease-free survival (DFS) rate of ficlatuzumab in combination with HiDAC and HiDAC alone in subjects achieving CR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Ficlatuzumab with HiDAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ficlatuzumab 20 mg/kg intravenously (IV) on Days 1 and 15 in combination with cytarabine 2 g/m2 IV per day on Days 2 through 7. Up to two additional doses can be administered - on Day 29, or on Days 29 and 43, if prolonged myelosuppression is experienced.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HiDAC alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cytarabine 2 g/m2 IV per day on Days 1 through 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ficlatuzumab</intervention_name>
    <description>Ficlatuzumab is a selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.</description>
    <arm_group_label>Ficlatuzumab with HiDAC</arm_group_label>
    <other_name>AV-299</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.</description>
    <arm_group_label>Ficlatuzumab with HiDAC</arm_group_label>
    <arm_group_label>HiDAC alone</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Arabinosylcytosine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of AML according to the WHO criteria, which defines relapsed or refractory&#xD;
             to induction therapy as follows:&#xD;
&#xD;
               1. First relapse within 12 months after date of first CR or CRi&#xD;
&#xD;
               2. Persistent AML documented by bone marrow biopsy at least 29 days after Day 1 of&#xD;
                  the first induction cycle of cytotoxic chemotherapy&#xD;
&#xD;
               3. Hypercellular bone marrow with greater than 20% cellularity and 10% blasts at&#xD;
                  least 14 days after the first induction cycle Day 1&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Prior induction therapy, consisting of no more than 2 cycles of cytotoxic chemotherapy&#xD;
             with at least one of the cycles consisting of anthracycline and cytarabine with&#xD;
             reasonable schedule/dose intensity according to the discretion of the Investigator&#xD;
&#xD;
          4. Histologically confirmed AML by hematopathology review performed within 4 weeks of&#xD;
             study entry. Secondary AML due to progression of myelodysplastic syndrome or&#xD;
             myeloproliferative neoplasms is acceptable for inclusion.&#xD;
&#xD;
          5. Prior treatment for myelodysplastic syndrome or myeloproliferative neoplasm with&#xD;
             hypomethylating agent or targeted agent is acceptable for inclusion&#xD;
&#xD;
          6. Ejection fraction ≥40% by echocardiogram or multigated acquisition (MUGA) scan&#xD;
&#xD;
          7. Cytoreduction therapy with leukapheresis or hydroxyurea is allowed&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&#xD;
&#xD;
          9. Clinical laboratory values meeting the following criteria before Day 1 (Cycle 1, Day&#xD;
             1):&#xD;
&#xD;
               1. An estimated glomerular filtration rate of ≥ 60mL/min based on Cockcroft-Gault&#xD;
                  equation calculated using serum creatinine levels&#xD;
&#xD;
               2. Total bilirubin ≤2.0 mg/dL (≤3.0 mg/dL for subjects with known Gilbert's&#xD;
                  syndrome)&#xD;
&#xD;
               3. Aspartate aminotransferase (AST) or ALT ≤2.5 × ULN, unless thought to be due to&#xD;
                  AML&#xD;
&#xD;
               4. Activated partial thromboplastin time ≤1.5 × ULN and prothrombin&#xD;
                  time/international normalized ratio (PT/INR) ≤1.5 × ULN if not on anticoagulation&#xD;
                  therapy. Subjects receiving anticoagulation therapy with an agent such as&#xD;
                  warfarin or low-molecular weight heparin may be allowed to participate with the&#xD;
                  therapeutic range established before initiation of study treatment.&#xD;
&#xD;
         10. For female subjects of childbearing potential, documentation of negative serum&#xD;
             pregnancy test before randomization&#xD;
&#xD;
         11. For female subjects of childbearing potential and male subjects whose sexual partners&#xD;
             are of childbearing potential, agreement to use an effective method of contraception&#xD;
             during the study and for at least 90 days after the last dose of ficlatuzumab.&#xD;
             Effective birth control includes (a) intrauterine device plus 1 barrier method; (b)&#xD;
             oral, implantable, or injectable contraceptive plus 1 barrier method; or (c) 2 barrier&#xD;
             methods. Effective barrier methods are male or female condoms, diaphragms, and&#xD;
             spermicides (creams or gels that contain a chemical to kill sperm).&#xD;
&#xD;
         12. Ability to give written informed consent and comply with protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of severe allergic or anaphylactic reactions or hypersensitivity to&#xD;
             recombinant proteins or excipients in the investigational agent or cytarabine&#xD;
&#xD;
          2. Acute promyelocytic leukemia (AML French-American-British classification M3)&#xD;
&#xD;
          3. More than 2 cycles of prior induction therapy for AML&#xD;
&#xD;
          4. Prior treatment with intermediate- or HiDAC (≥1 gm/m2)&#xD;
&#xD;
          5. Allogeneic or autologous hematopoietic cell transplantation within 90 days of study&#xD;
             entry&#xD;
&#xD;
          6. Prior treatment with any other investigational drugs, biologics, or devices, within 4&#xD;
             weeks before Day 1&#xD;
&#xD;
          7. Active graft versus host disease or immunosuppression for prevention or treatment of&#xD;
             graft versus host disease within 4 weeks of study entry&#xD;
&#xD;
          8. Chemotherapy or radiation therapy within 1 week before study entry, other than&#xD;
             hypomethylating agents or hydroxyurea used for cytoreduction&#xD;
&#xD;
          9. Significant cardiovascular disease, including:&#xD;
&#xD;
               1. Cardiac failure New York Heart Association class III or IV&#xD;
&#xD;
               2. Myocardial infarction, severe or unstable angina within 6 months before Day 1&#xD;
&#xD;
               3. History of serious ventricular arrhythmia (ie, ventricular tachycardia or&#xD;
                  ventricular fibrillation)&#xD;
&#xD;
         10. Significant thrombotic or embolic events within 3 months before Day 1 (significant&#xD;
             thrombotic or embolic events include, but are not limited to, venous thromboembolism,&#xD;
             stroke, or transient ischemic attack). Catheter-related thrombosis is not a cause for&#xD;
             exclusion. Diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it&#xD;
             occurred &gt;3 months before Day 1 and anticoagulation therapy is completed before Day 1.&#xD;
&#xD;
         11. Any other medical condition or psychiatric condition that, in the opinion of the&#xD;
             Investigator, might interfere with the subject's participation in the trial or&#xD;
             interfere with the interpretation of trial results&#xD;
&#xD;
         12. History of prior/concurrent malignancy whose natural history or ongoing treatment is&#xD;
             expected to interfere with the safety or efficacy assessment of the intervention&#xD;
&#xD;
         13. Known seropositive or active HIV&#xD;
&#xD;
         14. Active hepatitis B or C infection&#xD;
&#xD;
         15. Uncontrolled systemic fungal, bacterial, or viral infections&#xD;
&#xD;
         16. For female subjects, pregnant or breastfeeding&#xD;
&#xD;
         17. Prior exposure to the investigational agent or anti-c-MET, or anti-HGF within 6 months&#xD;
             before study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

